Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2007

View Archived Issues

First identified mutation in the sarcosine dehydrogenase gene may be associated with sarcosinemia

First-in-man study of tafluposide determines MTD in cancer patients

Long-term sitaxsentan monotherapy beneficial in pulmonary arterial hypertension

Qnexa improves quality of life in obese subjects

131I-TM-601 crosses blood-brain barrier in glioma patients

Anticancer activity seen with ARQ-197 in phase I metastatic cancer trial

Lantibio and TRB Chemedica enter licensing agreement with Alcon for dry eye drug

New immunosuppressant agents disclosed in recent Synta patent

Recent PainCeptor and Boehringer Ingelheim patents disclose novel analgesic agents

New agents for treating neurological disorders disclosed in recent patents

U.S. government appropriates USD 0.8 million for development of anthrax therapeutic

Immtech and Scynexis receive funding to develop treatments for African sleeping sickness

Results from a clinical study and safety update presented for Novartis's Galvus

GTx and Merck & Co. enter agreement to develop selective androgen receptor modulators

Meditor completes primary endpoint and safety evaluation in phase II study of MTR-106

FDA grants orphan drug designation to Kiadis Pharma's ATIR for graft-versus-host disease

Bavarian Nordic provides update on vaccine project pipeline

Verona Pharma initiates second 28-day experimental inhalation toxicology study of RPL-554

First patient undergoes StemEx transplant in ExCell registration study

Biovail enters agreement with Pharma Pass II for BVF-068 and BVF-247

Aeolus's AEOL-10150 demonstrates protection against mustard gas

Bionomics presents update on development of BNC-105 and BNC-210

FDA approves IND application for Metastatix's CXCR4 inhibitor MSX-122

AstraZeneca presents third quarter 2007 results

FDA approves new indication for AstraZeneca's Crestor in treatment of elevated cholesterol

Canadian researchers report an SOD1-targeted immunotherapeutic approach to familial ALS

Cognition-enhancing effects of new nAChR alpha7 partial agonist tested in monkeys

Selective GluR5 receptor antagonist shows antinociceptive activity in animal models

Potent antiprion compound identified from a series of pyrazolones

YJP-60295, a new caspase inhibitor with neuroprotective properties

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...